Skip to main content
Premium Trial:

Request an Annual Quote

New York Gives Final Approval for Rosetta Genomics' miRview Lung Assay

NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the New York State Department of Health has given the company's miRview lung assay final approval for marketing in the state.

As a result, the company can offer the microRNA-based test for the differentiation of the four main subtypes of lung cancer in all 50 states. New York had given the test, launched in July 2011, conditional approval in June.

"This represents an important validation of our technology as many jurisdictions around the world recognize the rigor of review in the state of New York," Rosetta President and CEO Kenneth Berlin said in a statement. "With the introduction of targeted lung cancer therapies, along with new targeted drugs entering the clinical arena, accurate classification of lung cancer is becoming increasingly important to better assess efficacy profiles and to enhance treatment strategies."

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.